BioInvent and ThromboGenics to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Trial to study patients with colorectal and ovarian cancer
19-May-2010 -
BioInvent International AB and ThromboGenics NV announcd that their partner Roche will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancer. BioInvent and co-development partner ThromboGenics ...
magnetic resonance imaging
milestone payments
ovarian cancer
+3